A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05) - ScienceDirect
Summary This article describes a Phase II clinical trial called SBRT-SG 05 that evaluated the use of stereotactic body radiation therapy (SBRT) combined with androgen deprivation therapy (ADT) in patients with oligometastatic prostate cancer. Here are the key points: 1. Study design: - Two cohorts: 1) Main cohort of 67 patients with hormone-sensitive prostate cancer 2) Exploratory cohort of 14 patients with castration-resistant prostate cancer - Patients received SBRT to metastatic lesions and ADT for at least 24 months - Median follow-up was 40 months 2. Main results: - 3-year local recurrence-free survival: 92.5% (62/67) in main cohort, 85.7% (12/14) in exploratory cohort - In main cohort at 3 years: - Biochemical relapse-free survival: 50.6% - Metastasis progression-free survival: 67% - Exploratory cohort had lower metastasis progression-free survival rates 3. Toxicity: - No grade III or higher toxicity - Only 2 patients (2.4%) developed grade II toxicity ...